| EQS-Ad-hoc: Merck KGaA / Key word(s): Study results Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued 24-Jun-2024 / 19:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients with unresected locally advanced head and neck cancer in a phase III clinical trial (TrilynX). The company decided to discontinue this study. The decision follows a pre-planned interim analysis performed by the study’s Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Given the totality of the data, the company decided to also stop the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy in patients who underwent resection of locally advanced head and neck cancer).
Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world. Esther Döringer Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany Phone: +49 151 1454 7809 Email: esther.doeringer@merckgroup.com Internet: https://www.merckgroup.com/en ISIN: DE0006599905 WKN: 659990 Indices: DAX Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX Contact: Esther Döringer, Head of Media Relations24-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151 72 - 2702 |
| E-mail: | Friederike.Segeberg@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 1931843 |
| End of Announcement | EQS News Service |
| |
1931843 24-Jun-2024 CET/CEST
